Bilberry

A European blueberry relative carrying a persistent WWII pilot myth. The night-vision claim is false; the eye evidence that does exist is about something else.

How Bilberry actually works

Anthocyanins that strengthen capillary basement membrane by stabilizing collagen cross-links, and improve retinal microcirculation specifically. They also have direct antioxidant activity in retinal tissue and appear to support rhodopsin regeneration.

Where to get Bilberry

The evidence for Bilberry

Graded by what exists behind each claim.

✅ Clinically validated

• Multiple trials of the night-vision claim in healthy people have been NEGATIVE. This is settled and the myth persists anyway.
• Trials report reduced eye fatigue and improved accommodation with screen use — small but replicated across several Japanese studies.
• Trials in diabetic retinopathy and glaucoma show improvements in retinal microcirculation. Small and preliminary.

📊 Correlative data

• The RAF night-vision story from the Second World War is the famous claim and it appears to be wartime myth rather than observation — controlled testing has not reproduced it. Genuine European traditional use for vascular and eye complaints does predate that story.

🧪 Theoretical / extrapolated benefits

• Anthocyanins support capillary integrity and regeneration of rhodopsin — the mechanism the pilot story was built on, which did not survive testing.

How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →

What Bilberry actually does

Bilberry is Vaccinium myrtillus, and the actives are anthocyanins — glycosides of cyanidin, delphinidin, malvidin, petunidin and peonidin, fifteen of them in a standardized extract, collectively labeled anthocyanosides. They are the reddest, most photogenic molecules in the supplement aisle and among the least bioavailable.

The famous mechanism, stated properly so it can be judged. Rhodopsin is the rod photopigment: an opsin protein holding 11-cis-retinal, which photoisomerizes to all-trans-retinal on absorbing a photon and must be recycled through the retinal pigment epithelium before the rod can fire again. Dark adaptation is rate-limited by that regeneration. The bilberry claim is that anthocyanins accelerate it, which would make night vision faster to arrive after a flash of headlights. That is a real, specific, falsifiable mechanism — and it has been tested in humans repeatedly and failed. A systematic review located twelve placebo-controlled trials of bilberry anthocyanosides for night vision and concluded the hypothesis was not supported Canter 2004. This site's own card says the same thing, and says it more bluntly than most: the wartime pilot story is myth.

The mechanism that fits the trials that did work is a muscle, not a pigment. The endpoints that have moved are accommodative: the ciliary muscle contracts to thicken the lens for near focus, and hours of screen work fatigue it. The objective measure is the high-frequency component of accommodative microfluctuation, HFC-1 — a small, involuntary oscillation of accommodation whose amplitude rises as the ciliary muscle strains. In 109 healthy adults aged 20 to 60, 240 mg a day of standardized bilberry extract for twelve weeks significantly improved post-load HFC-1 at weeks 8 and 12 (P = 0.014 and 0.017) Kosehira 2020. That is a different organ, a different physiology and a different claim from the one on the folklore, and it is the one with the better data.

Underneath both sits the plausible general action: capillary stabilization. Anthocyanins inhibit matrix metalloproteinases and cross-link collagen in the basement membrane, which is the standard explanation for the European venotonic tradition and for the retinal-microcirculation results. It is compatible with a molecule that is barely absorbed, because a capillary wall sees whatever is in plasma, and it does not require the compound to enter a photoreceptor.

Cell, rodent, human — and where it stops

In cells. Rhodopsin-regeneration and endothelial work with purified anthocyanins at 10–100 micromolar, hours. Standard polyphenol territory Manach 2005.

In rodents. Rats and mice given anthocyanin extracts orally at 50–200 mg/kg for days to weeks, reading retinal function and capillary permeability. Rats are nocturnal and rod-dominated, which makes them a flattering model for a night-vision claim and a poor one for a human cone-and-accommodation claim.

In people, and here is the arithmetic that decides everything else. Four elderly women drank an elderberry extract delivering 720 mg of total anthocyanins. Total urinary anthocyanin recovery over four hours was 554 ± 90 micrograms — 0.077% of what was swallowed. Six women ate 189 g of blueberries delivering 690 mg of anthocyanins, and recovered 23.2 ± 10.9 micrograms, 0.004% Wu 2002. Related work on elderberry confirms that anthocyanins are absorbed as intact glycosides and appear in plasma only at very low concentrations Milbury 2002. Round it generously and something between a hundredth and a tenth of one percent of an anthocyanin dose is accounted for in urine.

So the specific obstacle is a factor of roughly ten thousand. The dish runs at 10–100 micromolar. A 320 mg dose of a 36% anthocyanoside extract delivers about 115 mg of anthocyanins; at a tenth of one percent that is around 115 micrograms distributed through a body, which is nanomolar plasma at best Wu 2002Manach 2005. No formulation on the shelf closes that gap. Any true effect of bilberry is therefore either (a) produced by the phenolic-acid degradation products of anthocyanins, which circulate at far higher concentrations and for far longer than the parent pigments, or (b) local, in the gut lumen or on the capillary endothelium the blood touches. Both are legitimate hypotheses. Neither is what the label implies, and neither has been tested for this species.

The second obstacle is that the positive human trials are clustered. The eye-fatigue and accommodation studies are Japanese, modest, and use screen-worker populations Ozawa 2015Kosehira 2020. That is not a criticism of their conduct; it is a statement about how much independent replication exists, which is very little.

Bilberry — which form, and does it matter

The standardization percentage is the only number on the bottle that means anything. Bilberry fruit is roughly 0.5% anthocyanins; a standardized extract is 25–36%. Those are the same plant and differ seventy-fold in the compound the evidence is about. A label reading ‘bilberry 500 mg’ without a percentage is almost certainly fruit powder, and 500 mg of powder carries roughly 2.5 mg of anthocyanins against 115 mg in 320 mg of a 36% extract.

The trial doses are higher than this site's card. The eye-fatigue trial in video display terminal workers randomized 88 people, 43 completing on bilberry extract, at 480 mg/day for eight weeks, and reported alleviation of the task-induced fall in critical flicker fusion (p = 0.023) alongside improvement in fatigue symptoms Ozawa 2015. The accommodation trial used 240 mg/day for twelve weeks Kosehira 2020. The card here says 160–320 mg daily standardized to 25–36% anthocyanosides, which covers the lower trial and sits at half the higher one. If you are buying this for screen fatigue, 320–480 mg is the tested band.

Bilberry is not blueberry, and the substitution is common enough to matter. Vaccinium myrtillus is pigmented all the way through the flesh; the cultivated highbush blueberry, Vaccinium corymbosum, has white flesh and carries its anthocyanins in the skin. Adulteration of bilberry extract with cheaper anthocyanin sources is a documented supply-chain problem, and the tell is the anthocyanin fingerprint: bilberry's delphinidin-heavy profile is different from blueberry's cyanidin-heavy one. Ask for the chromatographic profile, not just the percentage.

Take it with food and split the dose. Anthocyanin plasma concentrations peak within one to two hours and are largely cleared within six Wu 2002Milbury 2002. Two doses a day put the compound in circulation across the working hours the accommodation claim is about; one morning dose does not.

What would have to be true, and how you would know it was not

1. Screen-related eye fatigue, measured rather than remembered, improving at 8–12 weeks on 320–480 mg/day. The objective read-outs used in the trials are critical flicker fusion after a visual load Ozawa 2015 and post-load accommodative microfluctuation Kosehira 2020, both of which need a clinic. The home substitute is a fixed near-work block — the same task, the same duration, the same time of day — scored 0 to 10 for ocular discomfort immediately at the end, ten days before starting and ten days at week eight. Predict a one-to-two-point fall from a baseline above five, and nothing from a baseline of two.

2. Night vision: no change. This is the prediction that cuts against the product and it is settled. Twelve placebo-controlled trials, reviewed, and the hypothesis unsupported Canter 2004. If you are buying bilberry to drive better at night, the best-organized evidence in this literature says you will get nothing, and no dose or formulation on the shelf changes that.

3. hs-CRP and the lipid panel: expect nothing at these doses. The systemic anti-inflammatory story runs into the 0.004–0.077% recovery arithmetic Wu 2002. Predict hs-CRP flat at twelve weeks. If it moves in someone starting above 2 mg/L, that is interesting and it argues for the phenolic-metabolite hypothesis rather than for the anthocyanins on the certificate of analysis.

4. Fasting glucose down 3–5 mg/dL, and this one has a safety consequence. The card notes modest glucose lowering, and the mechanism that fits a barely-absorbed polyphenol is lumen-side: inhibition of alpha-glucosidase and of intestinal glucose transport. That predicts an effect on post-meal glucose specifically, so a two-hour post-meal reading on a home meter is a better test than a fasting draw — and it predicts the effect disappears if you take the capsule away from food, which is a within-person experiment costing nothing but a fortnight.

What will fool you: the placebo response in eye-comfort questionnaires is large, and eye fatigue improves on its own when the week gets easier. This is why the trials measured flicker fusion and microfluctuation instead of asking people how their eyes felt Ozawa 2015Kosehira 2020.

What nobody has tested yet

Nobody has measured the phenolic metabolites in a bilberry trial. Anthocyanins are degraded in the gut and by colonic microbiota to protocatechuic acid, vanillic acid, syringic acid and gallic acid, which reach plasma concentrations orders of magnitude above the intact pigments and persist far longer Wu 2002Manach 2005. If bilberry works, the most likely explanation is that these metabolites are the actives. A trial that measured them alongside the accommodation endpoint Kosehira 2020 would either identify the active molecule or rule the hypothesis out. It has never been done for this species.

The rhodopsin claim has never been tested with modern instrumentation. The night-vision trials in the systematic review are old and used psychophysical dark-adaptation thresholds Canter 2004. Full-field electroretinography measures rod recovery kinetics directly and objectively. A negative ERG study would close a myth that has survived thirty years of negative behavioral testing; a positive one would be the most surprising result in this cohort.

No trial has compared bilberry against a matched anthocyanin dose from another source. If the delphinidin-heavy bilberry fingerprint matters, bilberry should beat an equal milligram dose of blackcurrant or blueberry anthocyanins on the accommodation endpoint. If it does not, the species on the label is marketing and the compound class is the product. This is a three-arm trial of eighty people for twelve weeks and nobody has run it.

And the dose–response is unknown at both ends. Two doses have been tested for eye endpoints, 240 mg and 480 mg Kosehira 2020Ozawa 2015, in different trials with different measures. Whether 160 mg does anything, and whether 960 mg does more, are both open — which is uncomfortable for a product sold across exactly that range.

Bilberry — its own safety story, not its category's

The antiplatelet effect is this fruit's real interaction and it is not theoretical. Anthocyanins inhibit platelet aggregation, and unlike the systemic antioxidant claims this one does not need the compound to reach a distant tissue — platelets are in the blood where the small amount that is absorbed actually goes. Additive with warfarin, apixaban, rivaroxaban, clopidogrel and aspirin at any dose. It is pharmacodynamic rather than metabolic, so it does not appear as a changed drug level; it appears as bruising, nosebleeds or a raised INR. Stop at least two weeks before surgery or dental extraction, and volunteer it, because the pre-operative questionnaire asks about prescription blood thinners and not about berries.

Glucose lowering is additive rather than alternative. Bilberry modestly lowers blood glucose, which on insulin or a sulfonylurea is a hypoglycemia risk rather than a benefit. The practical answer is a meter, before and two weeks after starting, not an assumption that a berry is too weak to matter.

The risk specific to this product is adulteration, and it is a purity problem rather than a pharmacology problem. Bilberry extract is expensive, anthocyanin content is easy to fake with cheaper sources or with synthetic dyes, and the assay most vendors publish reports total anthocyanin content rather than the anthocyanin profile. Buy from a vendor that publishes a chromatographic fingerprint and a heavy-metal assay, because a concentrated fruit extract concentrates whatever the fruit took up from the ground.

What this product is not. It is not a treatment for retinopathy, glaucoma or macular degeneration, and the retinal microcirculation studies that get cited for those indications are small and preliminary. Anyone with diabetic eye disease belongs in an ophthalmology clinic on a screening schedule, and a berry extract does not change that schedule. Gastrointestinal upset at higher doses is the ordinary complaint and is a tannin effect rather than an allergy.

Sources read for this page

• Canter PH, Ernst E. Anthocyanosides of Vaccinium myrtillus (bilberry) for night vision--a systematic review of placebo-controlled trials. Survey of Ophthalmology 2004 · PMID 14711439
• Ozawa Y, et al. Bilberry extract supplementation for preventing eye fatigue in video display terminal workers. Journal of Nutrition, Health & Aging 2015 · PMID 25923485
• Kosehira M, et al. A 12-Week-Long Intake of Bilberry Extract (Vaccinium myrtillus L.) Improved Objective Findings of Ciliary Muscle Contraction of the Eye: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Comparison Trial. Nutrients 2020 · PMID 32106548
• Wu X, et al. Absorption and metabolism of anthocyanins in elderly women after consumption of elderberry or blueberry. Journal of Nutrition 2002 · PMID 12097661
• Milbury PE, et al. Bioavailablility of elderberry anthocyanins. Mechanisms of Ageing and Development 2002 · PMID 12044949
• Manach C, et al. Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies.. American Journal of Clinical Nutrition 2005 · PMID 15640486

How you would know if it worked

Bilberry — safety & side effects

Bloodwork to run alongside Bilberry

Baseline first, then again at 8–12 weeks.

The Longevity Baseline panel covers these in one order — 13 markers, $219.10 with the discount applied.

Check results you already have → · All 103 markers A–Z

Bilberry — frequently asked questions

Bilberry inside a finished plan

One arm of 1 Protocol Blueprint, free to read in full.

What Bilberry is used for

Bilberry appears under 1 goal in the goal router.

Related Longevity & Antioxidants supplements

← Browse the full Supplement Vault

↑ Back to on this page